Drug Profile
Sapitinib - AstraZeneca
Alternative Names: AZD-8931Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator AstraZeneca
- Developer AstraZeneca; Cancer Research UK; University College London
- Class Antineoplastics; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; ERBB-3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Colorectal cancer
- Discontinued Advanced breast cancer; Gastric cancer; Oesophageal cancer; Solid tumours
Most Recent Events
- 17 Sep 2019 Chemical structure information added
- 02 Aug 2019 AstraZeneca completes a phase I/II trial in Colorectal cancer (Combination therapy, Late-stage disease) in United Kingdom (PO) (NCT01862003)
- 23 Sep 2016 Sapitinib is still in phase I/II trials for Colorectal cancer (Combination therapy, Late-stage disease) in United Kingdom (PO) (NCT01862003)